Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orqis tests CHF recovery system in US trial

This article was originally published in Clinica

Executive Summary

The US FDA has given Orqis Medical the green light to conduct a pivotal clinical trial of its catheter-based cardiac recovery system for treating congestive heart failure (CHF). The MOMENTUM trial will test the company's system, called Cancion, in up to 200 CHF patients at 40 centres. Cancion is the first therapy for CHF based on continuous aortic blood flow augmentation to the descending aorta, claims the Lake Forest, California firm. It is designed to allow the heart to rest while it recovers from an acute decompensation event.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT055101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel